Fc portion of human IgG1

Showing all 12 results

Filter our product list:

Product Batch	Antigen	Molecular Class	Drug Brand	Product Concentration	CoA	Quantity per vial	Storage Temperature	Expiry Date	Price from
Aflibercept KT05V26	PIGF , VEGF-A	Fusion protein	Eylea®	40 mg/mL	–	0,8 mg	-80°C	11/2021	548,10 €	view product Max: 1 Min: 1 Step: 1
Etanercept 2110190088	TNF alpha	Biosimilar , Fusion protein	Erelzi®	50 mg/mL	–	4 mg	-80°C	04/2023	237,60 €	view product Max: 10 Min: 2 Step: 1
Etanercept FL6599	TNF alpha	Fusion protein	Enbrel®	50 mg/mL	–	6 mg	-80°C	01/2024	266,00 €	view product Max: 10 Min: 2 Step: 1
Etanercept GR206474	TNF alpha	Biosimilar , Fusion protein	Benepali®	50 mg/mL	–	4 mg	-80°C	11/2023	264,00 €	view product Max: 10 Min: 2 Step: 1
Etanercept S67398	TNF alpha	Fusion protein	Enbrel®	25 mg/mL	–	2 mg	-80°C	02/2019	171,90 €	view product Max: 10 Min: 2 Step: 1
Etanercept T21782	TNF alpha	Fusion protein	Enbrel®	50 mg/mL	–	2 mg	-80°C	04/2019	171,90 €	view product Max: 10 Min: 2 Step: 1
Etanercept T64915	TNF alpha	Fusion protein	Enbrel®	50 mg/mL	–	2 mg	-80°C	06/2019	171,90 €	view product Max: 10 Min: 2 Step: 1
Etanercept W02981	TNF alpha	Fusion protein	Enbrel®	50 mg/mL	–	2 mg	-80°C	08/2019	171,90 €	view product Max: 10 Min: 2 Step: 1
Etanercept W32559	TNF alpha	Fusion protein	Enbrel®	25 mg/mL	–	2 mg	-80°C	12/2019	171,90 €	view product Max: 10 Min: 2 Step: 1
Etanercept W42283	TNF alpha	Fusion protein	Enbrel®	50 mg/mL	–	2 mg	-80°C	10/2019	171,90 €	view product Max: 10 Min: 2 Step: 1
Etanercept X44248	TNF alpha	Fusion protein	Enbrel®	50 mg/mL	–	2 mg	-80°C	04/2020	171,90 €	view product Max: 10 Min: 2 Step: 1
Etanercept Y10005702	TNF alpha	Biosimilar , Fusion protein	Nepexto®	50 mg/mL	–	4 mg	-80 °C	08/2023	237,60 €	view product Max: 10 Min: 2 Step: 1

Not looking for Fc portion of human IgG1?

Search our therapeutic molecules product database

Fc portion of human IgG1

Not looking for Fc portion of human IgG1?

Search our therapeutic molecules product database

© All rights reserved

Evidentic GmbH – Speeding up early drug development